Stay updated on biotech news by subscribing to our newsletter. This week’s highlights include the approval of Geron’s drug for blood cancer, the impact of the BIOSECURE Act on the industry, and FDA’s review of donanemab for Alzheimer’s. The BIO International Convention focused on national security in biotech, with concerns about Chinese suppliers. FDA advisors are questioning the use of donanemab only for patients with tau proteins. A bidding war for Vanda Pharmaceuticals is ongoing. Other topics include Italy’s antitrust case against pharma companies, Moderna’s mRNA candidate for rare diseases, and more. Listen to “The Readout LOUD” podcast for insights on psychedelics, ASCO, and Morphosys.
Source link
Geron, BIO, Eli Lilly, Vanda updates
